cryptocurrency research topics 2021 Top Featured

Citic Jiantou Pharmaceutical's 2025 strategy: looking for new additions and integration opportunities. Citic Jiantou said that looking forward to 2025, the reform policy in the medical field has been normalized, and the most noteworthy incremental policy in the medical insurance field is to establish a diversified payment system. The medical field is about to usher in the reform of "deep water areas" such as salary system and graded diagnosis and treatment, which is in line with expectations as a whole. At the same time, the innovation of China's pharmaceutical industry has gradually stepped onto the international stage, some sub-sectors will be marginally improved, and industry integration will begin. We are optimistic about the investment opportunities in the pharmaceutical industry in 2025. It is suggested to focus on the new increase (innovation, going out to sea, marginal change) and industry integration opportunities.Senior Advisor of Shi Pomao: Japan must be prepared for Trump tariffs. One of Japan's top security officials said that Japan needs to be prepared for the threat of US President-elect Trump to impose tariffs on Canada and Mexico, and adjust the supply chain to reduce the collateral damage to Japanese enterprises. Akihisa Nagashima, national security adviser to Japanese Prime Minister Shi Pomao, said that during his recent visit to the United States, he had a "frank" communication with Trump team members on tariff issues. "I realized that Japan must be ready for Trump to implement his plan," he said.Onlikon: The cooperative product Aidit calcitonin soft capsules is planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13th, and on December 12th, the company received a notice from its partner Beijing Meifurun Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Meifurun") that the Aidit calcitonin soft capsules jointly developed by the company and its wholly-owned subsidiary Wenzhou Haihe Pharmaceutical Co., Ltd. are planned to be selected for the tenth batch of national centralized drug procurement. According to the Pharmaceutical Cooperation Agreement signed by the company and its partner Mei Furun, the company owns 50% of the cooperative products.

A delegation of Japanese young and middle-aged military officers visited China. Today, Senior Colonel Wu Qian, director of the Information Bureau of the Ministry of National Defense and spokesman of the Ministry of National Defense, said that at the invitation of China Institute of International Strategic Studies, a delegation of Japanese young and middle-aged military officers will visit China from November 26th to December 4th. The Sino-Japanese exchange program for young and middle-aged officers began in 2001, which played an important role in enhancing understanding and trust between the defense departments of the two countries. We are willing to work with Japan to continue to promote mutual visits and exchanges and provide positive energy for the improvement and development of bilateral relations.The American medical insurance giant said that the suspect who assassinated its CEO was not a company customer. A spokesman for UnitedHealth Group said that Luigi Mangione, the suspect accused of killing Brian Thompson, CEO of the company's United Health Care, was not a member of the company's insurance plan. Unitedhealth group said that Man Ghione and his mother were not members of United Health Insurance Company, and refuted the claim that the shooting incident was caused by dissatisfaction caused by his special experience in the company.Li Tie's family members were not present at the trial today, and the verdict in the first instance of Li Tie's case will start at 8:30 on time today. It is understood that after the trial today, it will directly enter the sentencing procedure, and the presiding judge will read the verdict and then ask the parties whether to appeal. Besides, apart from the defense lawyer, Li Tie's family did not come to the scene. (CCTV)

Guotai Junan: It is expected that the lithium price will fluctuate in the bottom range in 2025, and there is a strong opportunity and space for rebound. Guotai Junan Securities recently reported that the lithium price has entered the bottom range by the end of 2024. If the demand maintains the current neutral estimate in 2025, the lithium price will fluctuate in the bottom range. At present, the market is optimistic about the demand in 2025, and the industry supply has slowed down. It is estimated that the price trend of lithium will fluctuate in the bottom range in 2025, in which the stage is affected by seasonal factors and there is a strong rebound opportunity and space. The market expected the trading of lithium plate earlier, that is, when the commodity price bottomed out, the lithium plate already contained the expectation of industrial clearing. When the industry actually enters the stage of supply and clearing, the sector will trade commodity price reversal expectations. From this, we infer that the rise of lithium plate will start before the spot price reverses.Full-page observation of People's Daily: Accelerate the construction of world-class universities and advantageous disciplines with China characteristics.Quobly established a strategic cooperative relationship with stmicroelectronics. On December 13th, Quobly, a start-up company of quantum computing, announced that it would cooperate with stmicroelectronics to provide services for customers in the field of electronic applications, so as to mass-produce quantum processor units (QPU). This cooperation will utilize stmicroelectronics's 28nm FD-SOI commercial semiconductor batch manufacturing process. According to the vision of Quobly and stmicroelectronics, the first generation of commercial products will be available in 2027, and the target application market includes material development and system modeling.